There are 33 papers on serum potassium in aging research: 9 trials and 16 observational studies in people, 1 in animals, 5 reviews.
33 papers study it42 more mention it14 findings
22 new papers in 30 daysSee all 75 papers on serum potassium
“elevated serum potassium were independently associated with both outcomes.”
- Human trial9
- Humans16
- Animals1
- In silico1
Interventions
7Baxdrostat
upin humans2
2 studies
Baxdrostat
upin humans2
Baxdrostat increases serum potassium in humans (uncontrolled or resistant hypertension; compared with placebo) (MD 0.39 mmol/L).
Reviewuncontrolled or resistant hypertension; compared with placebo0.5–2 mg12–24 weeks
Baxdrostat increases serum potassium in humans (uncontrolled and resistant hypertension; compared with placebo) (MD 0.4 mmol/L; 95% CI 0.26, 0.54).
Reviewuncontrolled and resistant hypertension; compared with placebon = 1,729
Finerenone
upin humans2
2 studies
Finerenone
upin humans2
Finerenone increases serum potassium in humans (CKD and T2D; sequential or simultaneous initiation with SGLT2 inhibitors) (Sequential: +0.16 mmol/L (95% CI +0.12 to +0.21); simultaneous: +0.22 mmol/L).
Human trialCKD and T2D; sequential or simultaneous initiation with SGLT2 inhibitors30 days
Finerenone increases serum potassium in humans (primary aldosteronism) (+0.39±0.05 mmol/L; normal concentration in 94.5% versus 61.8% at baseline).
Human trialprimary aldosteronism20-40 mg/d12 weeks
Dietary potassium intake
no changein humans1
1 study
Dietary potassium intake
no changein humans1
Dietary potassium intake was not clearly linked with serum potassium in humans (maintenance hemodialysis patients).
Humansmaintenance hemodialysis patients
Aldosterone synthase inhibitors
upin humans1
1 study
Aldosterone synthase inhibitors
upin humans1
Aldosterone synthase inhibitors increase serum potassium in humans (clinical trial populations) (Median increase of ∼0.3 mmol/l).
Reviewclinical trial populations
Spironolactone
upin humans1
1 study
Spironolactone
upin humans1
Spironolactone increases serum potassium in humans (on irbesartan background therapy).
Human trialon irbesartan background therapy20 mg/d72 weeks
Sodium zirconium cyclosilicate
downin humans1
1 study
Sodium zirconium cyclosilicate
downin humans1
Sodium zirconium cyclosilicate decreases serum potassium in humans (chronic hyperkalemia) (from 5.4 (5.1, 5.9) to 4.4 (4.2, 4.9) mEq/L).
Human trialchronic hyperkalemia3 monthsn = 24
Arm swing exercise
upin humans1
1 study
Arm swing exercise
upin humans1
Arm swing exercise increases serum potassium in older persons with prehypertension; compared with control group.
Human trialin older persons with prehypertension; compared with control group30 min/day, 3 days/week3 monthsn = 50
Associations
524-hour and 30-day all-cause mortality
upin humans1
1 study
24-hour and 30-day all-cause mortality
upin humans1
Serum potassium is associated with 24-hour and 30-day all-cause mortality in humans (Emergency department presentation with initial blood gas pH < 6.90; adjusted analysis).
HumansEmergency department presentation with initial blood gas pH < 6.90; adjusted analysis24 hours and 30 daysn = 413
Finerenone
upin humans1
1 study
Finerenone
upin humans1
Finerenone is associated with serum potassium in humans (Diabetic kidney disease) (+0.086 mmol/L).
HumansDiabetic kidney diseaseSix-month post-initiation period
Early Vascular Aging Ambulatory score
downin humans1
1 study
Early Vascular Aging Ambulatory score
downin humans1
Early Vascular Aging Ambulatory score is associated with serum potassium in treated hypertensive adults (r = -0.290, p = 0.038).
Humansin treated hypertensive adultsn = 50
Hypertension
downin humans1
1 study
Hypertension
downin humans1
Serum potassium is linked with a lower risk of hypertension in humans (elderly) (3.72 ± 0.46 vs 4.28 ± 0.40 mEq/L, p<0.001).
Humanselderlyn = 150
Mortality
upin humans1
1 study
Mortality
upin humans1
Serum potassium is associated with mortality in humans.
Humans